BMS' PEG-Interferon lambda as effective as alfa, fewer flu-like symptoms
This article was originally published in Scrip
Executive Summary
Bristol-Myers Squibb has provided the first sustained virologic response (SVR) results for its investigational PEG-Interferon lambda for patients with hepatitis C virus (HCV).